MedTrace Logo

Towards Cure Via Only Ultra-short ICB in CSCC

NCT06823479 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2025-05-29

No results posted yet for this study

Summary

The goal of this clinical trial is to determine whether cutaneous squamous cell carcinoma patients can be cured using only immunotherapy, without surgery or radiotherapy.

Conditions

Interventions

DRUG

Nivolumab

3 mg/kg

DRUG

Ipilumimab

1 mg/kg

Sponsors & Collaborators

  • UMC Utrecht

    collaborator OTHER

  • Erasmus Medical Center

    collaborator OTHER

  • Maastricht University Medical Center

    collaborator OTHER

  • Amsterdam UMC, location VUmc

    collaborator OTHER

  • The Netherlands Cancer Institute

    lead OTHER

Principal Investigators

  • Lotje Zuur, Prof. Dr. · The Netherlands Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-14
Primary Completion
2029-02-28
Completion
2029-02-28

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06823479 on ClinicalTrials.gov